Search Browse Earnings

Iterum Therapeutics plc — SlamSEC

Iterum Therapeutics plc

Nasdaq:ITRM

Pharmaceutical Preparations·DUBLIN 1, L2

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$37,000

-95.7% YoY

FY 2021

Adj. EBITDA

-$30.3M

-81889.2% margin

FY 2024

Net Income

-$44.4M

-120091.9% margin

FY 2024

EPS (Diluted)

-$3.63

FY 2024

Stock Price

$0.16

-3.2%

2026-03-09

52W Range

$0.14 – $1.50

P/E Ratio

-0.0x

Market Cap

$7.2M

Cash

$6.1M

FY 2024

Total Debt

$10.1M

FY 2023

Net Debt

$4.0M

FY 2023

Enterprise Value

$11.2M

Debt / EBITDA

-0.1x

FY 2021

EV / EBITDA

-0.4x

Employees

—